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Abstract For bulking agents used for female stress urinary
incontinence, the recommendation for the anatomical
placement varies as some injectables are to be placed close
to the bladder neck and others midurethrally. Aim of the
study was to determine if there are differences concerning
the outcome after transurethral collagen injections depend-
ing on the anatomical placement midurethrally or at the
bladder neck. We randomly assigned 30 elderly female
patients with urodynamic stress incontinence to either
transurethral collagen injection midurethrally or to the
bladder neck. Prior to injection and at ten month follow-up,
maximum urethral closure pressure (MUCP), functional
urethral length (FUL), maximum flow rate and cough test
were performed and the patient was asked to estimate her
bladder condition using a visual analogue scale. Postopera-
tive contentness was 8 (median, 95% confidence interval
5–9) in the midurethral group and 8 (median, 95% con-
fidence interval 7–10) in the bladder neck group with a p
value of 0.012, 95% confidence interval –2.464 to –0.2859,
in favour to midurethral injections. MUCP and FUL
increased significantly in both groups and flow rate
decreased in both groups. Continence was 66.6% in the
midurethral group and 60% for the bladder neck group
respectively. Both midurethral and bladder neck collagen
injections improve patients’ satisfaction almost equally with
a small advantage for midurethral injections.
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Introduction
If conservative management has failed, bladder neck
injections are the most minimal invasive therapy for urinary
stress incontinence. According to a recent systematic
review from the Cochrane Database [1], injection therapy
may represent a useful option for short-term symptomatic
relief amongst selected women with comorbidity that
precludes anaesthesia.
Bladder neck injections have a low complication rate.
Peri-urethral injectable agents have been used for the
treatment of urinary incontinence in women for the past
century. A variety of substances have been reported in the
peer reviewed literature including bovine glutaraldehyde
cross-linked (GAX) collagen, polytetrafluoroethylene (Tef-
lon), polydimethyl-siloxane elastomer (silicone), carbon-
coated zirconium beads, hyaluronic acid/dextranomer and
autologous tissues as fat and cartilage [1–5]. Collagen is
one of the best-documented substances [6–12]; however,
long-term success rates are not satisfactory [13]. Initially,
Teflon injections were applied, but the course of time
showed migration and complications and this material has
now been abandoned [14].
Success rates range from 26 to 75%, and this procedure
is generally not considered that effective.
Historically, the bladder neck used to be the anatomic
area to be addressed using surgery for stress incontinence:
Burch colposuspension and abdominal sling procedures
will lift the bladder neck by elevation of the bladder neck
[15, 16]. Newer techniques place artificial suburethral
slings under the mid-urethra [17] based on the “integral
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theory” presented by Petros and Ulmsten [18]. In their
“integral theory” impairment of the pubo-urethral ligaments
is one of the primary causes of stress urinary incontinence.
The authors conclude that to compensate for the insuffi-
ciency of the pubo-urethral ligaments, a narrow strip of
polypropylene is placed at the point of maximal urethral
closure pressure at the mid-urethra.
For bulking agents, the recommendation for the anatom-
ical placement varies, as some injectables are to be placed
close to the bladder neck and others mid-urethrally [19, 20].
The aim of the study was to determine if there are
differences concerning the outcome after transurethral
collagen injections for urodynamic stress incontinence
depending on the anatomical placement mid-urethrally or
at the bladder neck.
Materials and methods
The study was performed in the Department of Gynae-
cology, Frauenklinik, Inselspital Berne, Switzerland.
Between December 2004 and April 2006, we randomly
assigned elderly female patients with urodynamic stress
incontinence to either collagen injection mid-urethrally or
to the bladder neck. Randomisation was computer-assisted,
and all patients gave written and oral consent to the study.
At least 4 weeks before injection, an intradermal collagen
allergy test was performed using 0.1 ml Contigen® being
injected into the left forearm.
Urodynamic investigations were done before surgery.
Cystometry was performed in the sitting position with the
patient in the 45° upright position with a 6-French microtip
transducer which was introduced into the bladder for
intravesical pressure measurement, and a water-perfused
balloon catheter was introduced into the rectum for intra-
abdominal pressure measurement. Bladder was filled with a
rate of 20 ml/min with saline solution at 37°. Filling was
continued until the patient experienced a strong desire to
void. A cough stress test was performed every hundred
millilitres of filling. At bladder capacity pressure, flow
studies were performed. Urethra pressure profile was
performed at rest three times repetitively, and the maximum
urethra closing pressure (MUCP) and functional urethral
length were measured.
The patients were blinded to the group assignment. Due
to a different injection technique, the surgeon (AK) was not
blinded to the group assignment.
Before injection, a urinary tract infection was excluded,
and all patients received perioperatively sulfamethoxazol
commencing immediately before injection.
Injections were performed in operating theatre with the
patient in lithotomy position using a Wolf® transurethral
cystoscope with working channel and a 7-French injection
needle with shoulder. With this type of cystoscope (Wolf®
registered number 8252.041) and 25° optic, the injection of
bulking material is particularly easy, as it can be operated
single-handedly and is originally designed for this operation.
Depth of injection was defined by the shoulder of the
injection needle which is 8 mm long. The needle was inserted
until the shoulder reached urethral level in all patients.
Urethral length was measured before injection using a
transurethral catheter with a blocked intravesical balloon,
which was marked with a permanent marker at the level of
Table 1 Satisfaction and
urodynamics Bladder neck
preoperative
Bladder neck
postoperative
Mid-urethral
preoperative
Mid-urethral
postoperative
Satisfaction
(VAS, mean)
3.8 7.2 4 8.2
MUCP (cm H2O, mean) 20.7 41.9 23.6 27.1
Maximum flow rate
(ml/s, mean)
24.3 17.3 28.8 16.06
Functional urethral
length (mm, mean)
23.2 25.1 20.6 30.7
Positive cough test (n) 15 6 15 5
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Fig. 1 Postoperative patients’ satisfaction: A bladder neck injections,
B mid-urethral injection
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the external urethral meatus, then was withdrawn and the
distance to mid-urethra calculated dividing urethral length
by 2 for the mid-urethral group and the complete length for
the bladder neck group subtracting 5 mm.
In both groups, the desired distance was marked on the
cystoscope, the cystoscope was inserted until the mark was
reached, and Contigen® (Bard) was injected under visual
control until coaptation was reached. The injected material
and estimated leakage of material was noted. The procedure
was performed under local para-urethral anaesthetic with
2% lignocaine and intra-urethral lidocaine jelly.
Postoperatively, residual urine was measured using
trans-abdominal ultrasound, and residual urine was consid-
ered insignificant when it was less then 100 ml. The patient
was then discharged. Follow-up took place after 6 weeks
and 10 months and included patient satisfaction using a
visual analogue scale (VAS) with the least satisfaction
being a 0 and the most satisfaction being a 10. Rate of 0–3
was considered not satisfied, 4–7 moderately satisfied and
more than 8 as satisfied. The exact wording to determine
satisfaction was “How satisfied are you with the current
bladder condition?”
Residual urine was measured using ultrasound, urethral
resting pressure and functional urethral length; cough test at
bladder capacity and flowmetry were performed as well.
Cough test was noted positive when any leakage could be
detected.
Statistics were performed using the InStat system version
4.0 for windows.
We calculated a power of 80% with a significance level
α=0.05 and the assumption of the true difference between
means of 3 on VAS if we had 15 patients in each group.
The expected standard deviation was assumed 3 because of
our classification of contentment.
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Fig. 2 Mid-urethral injection: MUCP pre- (E) and postoperative (F)
Mean and Standard Deviation
Column
G H
32
30
28
26
24
22
20
18
16
14
12
10
8
6
4
2
0
Fig. 3 Bladder neck injection: MUCP pre- (G) and postoperative (H)
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Fig. 4 Mid-urethral injection: Flow pre- (I) and postoperatively (J)
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Fig. 5 Bladder neck injection: Flow pre- (K) and postoperatively (L)
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Results
Thirty patients participated in this study.
Patients in the bladder neck group were 77.5 years old
(median; range 62–92), had a body mass index (BMI) of 27
(median; range 19–33) and had a parity of 2 (median; range
0–3). Patients in the mid-urethral group were aged 68
(median; range 48–89), had a BMI of 27 (median; range
21–34) and had a parity of 2 (median; range 1–3).
Both patient groups did not differ significantly con-
cerning age (p=0.8493), BMI (p>0.9999) or parity.
Table 1 describes patients’ satisfaction and urodynamic
results pre- and postoperatively.
Postoperative satisfaction was 8 (median, 95% confi-
dence interval 5–9) in the mid-urethral group and 8 (median,
95% confidence interval 7–10) in the bladder neck group
with a p value of 0.012, 95% confidence interval −2.464 to
−0.2859 in favour to mid-urethral injections (Fig. 1).
After mid-urethral injection, maximal urethral closure
pressure (MUCP) increased significantly postoperatively
(p<0.0001, 95% confidence interval −26.074 to 16.326;
Fig. 2).
After bladder neck injection, MUCP increased signifi-
cantly postoperatively (p=0.0003, 95% confidence interval
−5.032 to 1.768; Fig. 3).
Maximum flow rate decreased significantly postopera-
tively after mid-urethral injection (p=0.0001, 95% confi-
dence interval 7.13–18.336; Fig. 4).
In addition, after bladder neck injections, maximum flow
rate decreased significantly postoperatively (p=0.0002,
95% confidence interval 3.625 to 9.841; Fig. 5).
Postoperative acute retention occurred in four women of
the mid-urethral group and in none of the bladder neck
group. Retention lasted for 24 to 48 h, and urine was
drained by intermittent catheterization using eight Charriere
catheters.
No patient suffered from urinary tract infection
postoperatively.
Discussion
The current study proves that transurethral collagen
injections for female stress urinary incontinence improve
significantly the patients’ satisfaction and their continence.
However, we were unable to show a clear superiority of
either of the techniques, which may also be due to the small
sample size.
The success rates with 66.6% being dry on follow-up in
the mid-urethral group and 60% in the mid-urethral group,
respectively, correspond with the literature [7, 8] and are
very similar compared with each other. Possibly, the
shortness of the female urethra and the “traveling” [13] of
the collagen make it difficult to distinguish between bladder
neck and mid-urethral placement.
Ideally, the anatomical placement of bulking agents is
between the vascular sub-endothelial layer and the muscu-
lar layer that allows travelling of the substance between
layers and allows coaptation [13]. An anatomical study of
the female urethra showed the absence of a well-defined
sphincteric structure in the bladder neck region, whereas the
majority of thick rhabdomyosphincter fibres could be
detected in the middle and caudal thirds of the urethra
[21]. We wonder if this structural difference might be the
reason for the difference in postoperative retention of four
women in the mid-urethral group vs none in the bladder
neck group. The mid-urethral injection into the rhabdo-
myosphincter has possibly bulked the sphincter itself,
resulting in postoperative retention, whereas during bladder
neck injections, the injectable “disappeared” into connec-
tive tissue and the smooth muscle which is described in that
study as being rather delicate [21]. To be certain where the
collagen went, we would have had to use imaging
techniques which we did not [22]. By using our standard
injection technique with the needle shoulder as measure-
ment for depth, we cannot be definitely certain to inject into
the correct layer, but from our experience with permanent
bulking materials (ethylene vinyl alcohol), we know from
animal studies that we are sub-endothelially in 90% of
cases (Bard©, Data on file).
A weakness of the study is that the surgeon could not be
blinded to the technique, but a different team followed
patients up. However, this team had the opportunity to
check operating notes and could have found out about the
technique, which may add bias to the study.
Another weakness of this study is short follow-up and the
rather small number of patients. We know from other studies
that collagen is disappearing due to collagenase activity and
that 26% only are still continent after 5 years of treatment
[14]. The only difference in data between the mid-urethral
and the bladder neck group was obvious looking at
patients’ contentment which was statistically significant in
favour to mid-urethral injections. However, statistically
significant does not always mean clinically significant.
In conclusion, we may say that both mid-urethral and
bladder neck collagen injections improve patients’ satisfac-
tion almost equally, with a small advantage for mid-urethral
injections.
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